UK-US trade deal good news for UK life sciences, ABPI says
The UK-US trade agreement is good news for NHS patients and will support the UK life sciences industry, the Association of the British Pharmaceutical Industry (ABPI) says.
The agreement will ensure that UK pharmaceutical exports to the US continue to face 0% tariffs for three years. In 2024, the UK exported £6.6 billion ($8.7 billion) worth of medicinal and pharmaceutical products to the US in 2024.
A key tenet of the deal will be an increase to the baseline threshold used by the National Institute for Health and Care Excellence (NICE) to assess if medicines can be used by the NHS. The prices of existing medicines used by the NHS will not be affected but, in the future, new medicines will be assessed under revised cost-effectiveness thresholds.
The government will ask NICE to increase its baseline threshold from £20,000-£30,000 ($26,000-$40,000) to £25,000-£35,000 ($33,000-$46,000), giving NICE the opportunity to approve more new medicines and allowing a greater number of patients to benefit from those medicines. This increase to the threshold is up 25% at the lower end, and 17% at the upper end.
“The deal is an important step towards ensuring patients can access innovative medicines needed to improve wider NHS health outcomes,” said Richard Torbett, Chief Executive of the ABPI.
“It should also put the UK in a stronger position to attract and retain global life science investment and advanced medicinal research.”
UK to increase investment in medicines
The trade deal commits the UK to addressing what the ABPI calls the country’s past decade of underinvestment in medicines, which has seen the proportion of health spending on medicines fall from around 14% to 9%. Over the next 10 years, the country will increase investment in new medicines from around 0.3% of GDP to 0.6% of GDP, with key target milestones along the way.
To ensure this is delivered, the UK will reduce the level of repayments on NHS sales required from companies under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG), which currently requires companies to repay 23.5% of their NHS sales revenues.
The repayment rate for newer medicines in the VPAG scheme will be capped so that it will not exceed 15% for the next three years 2026-2028, with adjustments made to ensure companies do not need to self-fund the changes to the NICE threshold. Critically, the deal calls for rapid talks between the ABPI and the UK government to design and agree a new, more sustainable scheme model from 2029 onwards.
“These commitments begin to address industry concerns on NHS access to medicines, and the UK’s record-high and unpredictable payment rate,” Torbett added.
“There remain a great many details to work out and further technical improvements to make, but with this strong and positive progress, I look forward to working with the government to ensure this plan delivers for the NHS, patients and UK industry.”
Bruno Quinney, Content Team, DDW
